Recently, small-molecule covalent inhibitors have been accepted as a practical tool for targeting previously “undruggable” proteins. The high target selectivity of modern covalent inhibitors is now alleviating toxicity concerns regarding the covalent modifications of proteins. However, despite the tremendous clinical success of current covalent inhibitors, there are still unmet medical needs that covalent inhibitors have not yet addressed. This review categorized representative covalent inhibitors based on their mechanism of covalent inhibition: conventional covalent inhibitors, targeted covalent inhibitors (TCIs), and expanded TCIs. By reviewing both Food and Drug Administration (FDA)-approved drugs and drug candidates from recent literature, we provide insight into the future direction of covalent inhibitor development.
α-Galactosylceramide (α-GalCer) is a prototypical antigen recognized by natural killer T (NKT) cells, a subset of T cells crucial for immune regulation. Despite its significance, the complex structure-activity relationship of α-GalCer and its analogs remains poorly understood, particularly in defining the structural determinants of NKT cell responses. In this study, we designed and synthesized potential immunomodulatory ligands targeting NKT cells, inspired by glycolipids derived from the gut symbiont Bacteroides fragilis. A series of α-GalCer analogs with terminal iso-branched sphinganine backbones was developed through rational modification of the acyl chain. Our results identified the C3′ hydroxyl group as a structural element that impairs glycolipid presentation by CD1d, as evidenced by reduced IL-2 secretion and weak competition with a potent CD1d ligand. Notably, among C3′-deoxy α-GalCer analogs, those containing an α-chloroacetamide group exhibited robust NKT cell activation with Th2 selectivity. Computational docking and mass spectrometry analyses further confirmed the substantial interaction of α-chloroacetamide analogs to CD1d. These findings underscore the potential of leveraging microbiota-derived glycolipid structures to selectively modulate NKT cell functions for therapeutic purposes.
Peptidomimetics have matured from motif‑based inhibitors into a structural engineering discipline that systematically translates peptide recognition surfaces into drug‑like scaffolds. Driven by the urgent clinical demand to overcome the inherent pharmacological liabilities of biomolecules, the field is undergoing a decisive Peptide‐to‐Small Molecule paradigm shift—functionally converting peptide‐derived recognition motifs into orally bioavailable synthetic therapeutics. This Perspective highlights how foundational geometric design principles—linear repetition, convergent fusion, and cyclization—define next‑generation architectures capable of targeting complex protein–protein interactions (PPIs). Repeating‑unit oligomers exemplify linear projection strategies, heterocycle‑centered scaffolds embody the convergent fusion of recognition motifs, and macrocyclic frameworks pre‐organize bioactive conformations while enabling access to non‑canonical topologies. Beyond simple mimicry, these architectures increasingly embrace dynamic responsiveness, aggregation remodeling, and universal multi‑structure platforms. We argue that the convergence of geometric logic with automated synthesis and AI‑driven design will transform peptidomimetics into a primary modality for decoding and therapeutically engaging the human interactome, including historically “undruggable” PPIs.
10 August 2026 in Angewandte Chemie International Edition
Peptidomimetics have matured from motif‑based inhibitors into a structural engineering discipline that systematically translates peptide recognition surfaces into drug‑like scaffolds. Driven by the urgent clinical demand to overcome the inherent pharmacological liabilities of biomolecules, the field is undergoing a decisive Peptide‐to‐Small Molecule paradigm shift—functionally converting peptide‐derived recognition motifs into orally bioavailable synthetic therapeutics. This Perspective highlights how foundational geometric design principles—linear repetition, convergent fusion, and cyclization—define next‑generation architectures capable of targeting complex protein–protein interactions (PPIs). Repeating‑unit oligomers exemplify linear projection strategies, heterocycle‑centered scaffolds embody the convergent fusion of recognition motifs, and macrocyclic frameworks pre‐organize bioactive conformations while enabling access to non‑canonical topologies. Beyond simple mimicry, these architectures increasingly embrace dynamic responsiveness, aggregation remodeling, and universal multi‑structure platforms. We argue that the convergence of geometric logic with automated synthesis and AI‑driven design will transform peptidomimetics into a primary modality for decoding and therapeutically engaging the human interactome, including historically “undruggable” PPIs.